Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

ImmunityBio (IBRX) Non Operating Investment Income (2020 - 2025)

ImmunityBio (IBRX) has disclosed Non Operating Investment Income for 6 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • Quarterly Non Operating Investment Income rose 93.6% to $2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.4 million through Dec 2025, down 19.69% year-over-year, with the annual reading at $6.4 million for FY2025, 19.69% down from the prior year.
  • Non Operating Investment Income for Q4 2025 was $2.3 million at ImmunityBio, up from $2.1 million in the prior quarter.
  • The five-year high for Non Operating Investment Income was $8.9 million in Q1 2021, with the low at -$6.9 million in Q4 2021.
  • Average Non Operating Investment Income over 5 years is $416050.0, with a median of $872000.0 recorded in 2022.
  • The sharpest move saw Non Operating Investment Income tumbled 4087.25% in 2021, then surged 5037.14% in 2024.
  • Over 5 years, Non Operating Investment Income stood at -$6.9 million in 2021, then skyrocketed by 44.95% to -$3.8 million in 2022, then surged by 112.69% to $484000.0 in 2023, then soared by 145.25% to $1.2 million in 2024, then surged by 93.6% to $2.3 million in 2025.
  • According to Business Quant data, Non Operating Investment Income over the past three periods came in at $2.3 million, $2.1 million, and $1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.